Publicly available ChIP-Seq showed that MYC binding occurs within the promoter regions of multiple mtDNA replisome genes in a prostate cancer cell line and that this binding is reduced after MYC inhibitor treatment; RNA-Seq data show that their transcripts were reduced correspondingly (74) (Supplemental Figure 6B). Here, MYC is linked to prostate cancer.